In Good Company with Nicolai Tangen cover image

HIGHLIGHTS: David Ricks - CEO of Eli Lilly

In Good Company with Nicolai Tangen

00:00

Intro

This chapter explores the recent advancements in GLP-1 medications developed by a leading pharmaceutical company, tracing their historical roots and evolution over the past two decades. The discussion also highlights the potential broader impacts of these drugs, particularly regarding neurological health and metabolic control.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app